Delaware courts have tightened the requirements for admitting scientific evidence in drug liability claims, making it substantially harder for plaintiffs to establish causation through expert testimony alone. This shift follows a growing national trend in which judges serve as gatekeepers for scientific evidence, scrutinizing the methodologies, peer review, and general acceptance of studies offered to prove that a pharmaceutical product caused injury. The change means that plaintiffs’ experts must now demonstrate not just that a drug *could* cause harm, but that reliable scientific methodology supports their specific conclusion that it *did* cause harm in that individual case.
The practical effect is significant: cases that might have survived summary judgment motions in previous years now face dismissal before trial. For example, a plaintiff claiming that a blood pressure medication caused her stroke must present evidence of the drug’s mechanism of harm that meets stricter scrutiny—not merely cite studies showing the drug carries a known stroke risk. Delaware courts are asking whether the plaintiff’s expert has applied an appropriate comparison group, controlled for confounding variables, and used statistical methods that would be accepted in the scientific community, not just in the courtroom.
Table of Contents
- What Does “Raising the Bar” for Scientific Evidence Mean in Drug Liability Cases?
- The Gatekeeping Function and Its Impact on Causation Testimony
- How Plaintiffs Can Strengthen Scientific Evidence in Drug Cases
- Comparing Delaware’s Standard to Other Jurisdictions’ Approaches
- Common Pitfalls in Drug Liability Expert Reports
- The Role of Dose-Response Relationships and Temporal Issues
- Moving Forward: What Drug Liability Plaintiffs Should Know
What Does “Raising the Bar” for Scientific Evidence Mean in Drug Liability Cases?
Raising the evidentiary bar means courts are demanding more rigorous scientific foundation before allowing experts to testify that a drug caused a specific person’s injury. Historically, many courts permitted experts to rely on general causation (the drug can cause this type of harm) plus temporal association (the plaintiff took the drug and then got sick) plus differential diagnosis (ruling out other causes). Delaware courts are now requiring that the expert’s reasoning method itself be grounded in established science—not just that the conclusion happens to be plausible. This tightening typically involves three specific requirements.
First, the expert’s methodology must be generally accepted in the relevant scientific community, not merely invented for litigation. Second, the expert must disclose whether the method would produce different results if applied to a different patient, demonstrating that the reasoning is based on science rather than advocacy. Third, courts scrutinize whether the expert has applied objective, pre-determined criteria for inclusion or exclusion, or whether the analysis appears tailored to reach a particular plaintiff’s desired conclusion. A key limitation to understand: this standard does not require absolute certainty, but it does require that the scientific method, as applied, meets professional norms for hypothesis testing and data analysis.
The Gatekeeping Function and Its Impact on Causation Testimony
Delaware courts, like federal courts, function as gatekeepers that can exclude expert testimony under reliability standards. The gatekeeping role is not about second-guessing scientific conclusions but about ensuring that the method used to reach those conclusions is sound. When a plaintiff’s expert testifies that a statin caused liver damage, the court may ask: What is the rate of this outcome in the general population? In people who took the statin? In people who took a placebo? If the expert cannot answer these questions or offers only anecdotal reasoning, the testimony may be excluded. The warning here is critical: plaintiffs face a new burden of proof at the threshold stage.
Before any jury ever hears testimony, defendants can file motions to exclude expert evidence that fails the reliability standard. This means cases can be resolved in the defendant’s favor months before trial, based solely on whether the scientific evidence meets judicial scrutiny. A common example of testimony that now faces exclusion is the “temporal proximity” argument alone—the assertion that because the plaintiff took the drug shortly before becoming ill, causation is proved. Courts now require evidence that this temporal relationship, combined with dose-response correlation or biological plausibility grounded in accepted science, supports the expert’s conclusion.
How Plaintiffs Can Strengthen Scientific Evidence in Drug Cases
Plaintiffs’ attorneys have adapted by requiring their experts to conduct more rigorous differential diagnosis, document their methodology in advance, and reference peer-reviewed literature that supports their analytical approach. One example of strengthened evidence is the use of epidemiological studies to establish baseline incidence rates. If a plaintiff claims that an antidepressant caused suicidal ideation, the expert should cite studies on the baseline rate of suicidal ideation in the untreated population and in treated populations, then explain how the plaintiff’s clinical presentation fits within—or deviates from—those established patterns.
Another approach is having experts use objective criteria from the medical literature to assess whether alternative causes are plausible. For instance, if a patient developed kidney disease after starting a specific blood pressure medication, the expert might apply clinical guidelines that predict kidney disease risk based on age, baseline kidney function, diabetes status, and prior medication exposure. If the plaintiff’s condition tracks precisely with what those guidelines predict, the evidence is stronger. However, a limitation of this approach is that it requires more work and cost upfront: experts must prepare detailed reports, background literature reviews, and often respond to critiques from defense experts before trial.
Comparing Delaware’s Standard to Other Jurisdictions’ Approaches
Delaware’s heightened scrutiny represents a middle ground between the most permissive and most restrictive approaches to expert evidence. Some states have adopted very stringent “robust scientific methods” standards that closely mirror Daubert principles and exclude testimony based on isolated case reports or unpublished hypotheses. Other states take a more permissive approach, allowing expert testimony so long as the expert has some relevant experience and the conclusion is not entirely speculative.
Delaware’s position is that scientific evidence should meet standards comparable to those in the peer-reviewed literature and clinical practice—a rigorous but not impossible threshold. The tradeoff is that while this approach protects juries from junk science and prevents cases from turning on speculation, it also potentially excludes testimony from treating physicians and clinical experts who may have observed the drug’s effects in their individual patient. A cardiologist who treated the plaintiff and observed symptoms consistent with a known cardiac risk of the drug may still face exclusion if the court determines that the treating physician’s methodology for attributing causation does not meet the scientific standard. This creates a practical challenge for plaintiffs: they must present scientific evidence, not just clinical judgment, even when the treating physician’s observations are detailed and credible.
Common Pitfalls in Drug Liability Expert Reports
One of the most common mistakes is relying on animal studies or laboratory data without demonstrating that the findings translate to the human population or to the specific dose the plaintiff received. A study showing that a drug damages liver cells in culture does not establish that the dose used in humans produces the same effect. Courts now require explicit bridging: how does the in vitro finding relate to in vivo human exposure? Without that connection, the expert’s reasoning is incomplete.
Another pitfall is circular logic in differential diagnosis. An expert might testify, “I ruled out infection, I ruled out autoimmune disease, and I ruled out genetic factors, so it must be the drug.” But if the expert lacks objective criteria for each exclusion—or if the criteria were applied more stringently to alternative causes than to the drug hypothesis—the court may find the reasoning unreliable. The warning is that plaintiffs must ensure their experts document not just what they ruled out, but *how* and *why* they ruled it out, using the same scientific standard for each alternative cause.
The Role of Dose-Response Relationships and Temporal Issues
Dose-response evidence—showing that higher doses correlate with greater harm—strengthens scientific causation claims significantly. If a plaintiff took a higher dose of a drug than recommended, experienced severe symptoms, and then improved after dose reduction, a court is more likely to find the causation evidence reliable because dose-response is a recognized principle in toxicology and pharmacology. However, many drugs have complex dose relationships that do not follow a simple linear pattern, and some adverse events occur at standard doses in a small percentage of users, making dose-response analysis incomplete or uninformative.
Temporal issues also matter more under the heightened standard. The expert should explain not just that the symptoms appeared after drug exposure, but that the latency period (time from exposure to symptom onset) fits known pharmacological mechanisms. A drug that typically causes symptoms within days presents differently from one with a delayed onset of weeks or months. If the plaintiff’s timeline does not match the established timeline for the drug’s known adverse effect, the expert must explain why, or the court may exclude the testimony as inconsistent with accepted science.
Moving Forward: What Drug Liability Plaintiffs Should Know
The Delaware court’s elevated standard means that case evaluation must happen earlier and more carefully. Before filing suit, plaintiffs should obtain expert reports from qualified scientists or physicians who can articulate their methodology clearly and ground their opinions in peer-reviewed literature or accepted clinical guidelines. A vague expert report that concludes “the drug probably caused the injury” will not survive judicial scrutiny; a detailed report explaining the analysis, the comparison population, the alternative causes considered, and the scientific basis for attribution has a substantially better chance.
Defendants, conversely, have gained leverage through motions to exclude expert evidence before trial. These motions are now more likely to succeed if the plaintiff’s experts lack rigorous methodology or cannot articulate their reasoning in scientific terms. The ultimate result is a bifurcated system: cases with weak expert evidence may be dismissed before trial, while cases with strong, methodologically sound evidence proceed to jury trial on a more level playing field.